MindMaze Therapeutics Holding SA (SIX: MMTX), a global leader in scalable precision neurotherapeutics, announced the results of its Annual General Meeting held earlier today. Shareholders approved all proposals submitted by the Board of Directors, except the proposed increase in conditional share capital, which did not obtain the required qualified majority.
Shareholders re-elected Walid Hanna, Olaf Blanke and Martin Reiss to the Board of Directors and elected Brad Hollinger, Founder, Chairman and Chief Executive Officer of Vibra Healthcare, and Zach Henderson, Chief Executive Officer of MindMaze Therapeutics, as new members of the Board of Directors. These appointments bring additional expertise in healthcare operations and corporate leadership to the board.
In addition, shareholders approved the 2025 Annual Report and financial statements, the appropriation of available earnings, the discharge of the members of the Board of Directors and the Executive Committee, the re-election of Walid Hanna as Chairman of the Board of Directors, the elections to the Nomination and Compensation Committee, the re-election of the Independent Proxy and the statutory auditor, the compensation proposals for the Board of Directors and Executive Committee, and the consultative vote on the 2025 Compensation Report.
The rejection of the conditional capital increase proposal is noteworthy, as it may impact the company's ability to issue shares for future financing or acquisitions without calling another shareholder vote. However, the strong approval of other governance and compensation items indicates broad support for the current strategic direction.
Further information on the proposals submitted to shareholders is available in the AGM Invitation. Detailed voting results will be published on the Company’s website later today. The company continues to advance its mission of redefining recovery for neurological disorders through its FDA-cleared and CE-marked products.
MindMaze Therapeutics, listed on the SIX Swiss Exchange under ticker MMTX, focuses on integrating advanced software, proprietary sensors, and AI-driven data analytics to provide a continuum of care from acute hospital to home-based therapy. Its solutions address stroke, Parkinson’s disease, and other neurological conditions, aiming to alleviate the systemic shortage of specialized clinicians. For more information, visit www.mindmazetherapeutics.com.
